Ascendis Pharma A/S

Ascendis Pharma Misses on EPS, Stock Down 4.92%

Ascendis Pharma's earnings report showed a loss per share of $-0.59, which did not meet any consensus expectations. The stock reacted negatively, declining by 4.92%, likely due to the lack of revenue details and guidance. Investors may be concerned about the company's financial trajectory without further insights from management.